Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional Results available

An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)

ClinicalTrials.gov ID: NCT02997176

Public ClinicalTrials.gov record NCT02997176. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A PHASE I OPEN-LABEL PHARMACOKINETICS AND SAFETY STUDY OF TALAZOPARIB (MDV3800) IN PATIENTS WITH ADVANCED SOLID TUMORS AND NORMAL OR VARYING DEGREES OF HEPATIC IMPAIRMENT

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a trial to investigate the pharmacokinetics (PK) and the safety of talazoparib in patients with advanced solid tumors and impaired hepatic function.

Study identification

NCT ID
NCT02997176
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Pfizer
Industry
Enrollment
38 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2016 (Actual)
Primary completion
Feb 12, 2020 (Actual)
Completion
Feb 12, 2020 (Actual)
Last update posted
Feb 25, 2021

2016 – 2020

United States locations

U.S. sites
11
U.S. states
3
U.S. cities
10
Facility City State ZIP Site status
UCLA Hematology/Oncology - Alhambra Alhambra California 91801 —
CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center Bakersfield California 93309 —
St. Joseph Heritage Healthcare Fullerton California 92835 —
St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare Fullerton California 92835 —
UCLA Hematology/Oncology Los Angeles California 90095 —
UCLA Hematology/Oncology - Porter Ranch Porter Ranch California 91326 —
UCLA Hematology/Oncology - Santa Monica Santa Monica California 90404 —
UCLA Torrance Oncology Torrance California 90505 —
UCLA Hematology/Oncology - Santa Clarita Valencia California 91355 —
Orlando Health, Inc. Orlando Florida 32806 —
The University of Texas MD Anderson Cancer Center Houston Texas 77030 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02997176, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 25, 2021 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02997176 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →